Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Prostatic Neoplasms 22Prostatic Neoplasms, Castration-Resistant 6Neoplasm Metastasis 4Breast Neoplasms 3Neoplasms 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer 2Hormone Refractory Prostate Cancer 2Bone Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Fractures, Bone 1Castration-resistant Prostate Cancer 1Castrate-Resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1Bone Metastases 1Bone Diseases 1

Interventions

Dexamethasone 307Bortezomib 161Lenalidomide 130pomalidomide 112daratumumab 94carfilzomib 69Calcium Dobesilate 41Cyclophosphamide 40belantamab mafodotin 31elotuzumab 30fludarabine 27ixazomib 23isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Multiple Myeloma × radium Ra 223 dichloride × Clear all
NCT02928029 2020-02-26

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

Bayer

Phase 1/2 Terminated
7 enrolled 9 charts
Plasma cell

Multiple Myeloma

NCT02605356 2016-10-07

Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma

Bayer

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡